



**EVALUATION OF PANCREATIC CYST PROSTAGLANDIN E2 AS
A MARKER FOR DIFFERENTIATION BETWEEN MUCINOUS
AND NON MUCINOUS CYSTS AND PREDICTION OF
DYSPLASIA IN MUCINOUS PANCREATIC CYSTS**

Thesis

Submitted for partial fulfillment of Master degree in Internal Medicine

Presented by

Heba Hassan Abd El Rady Abd El Halim

(M.B., B.Ch), Ain Shams University

Supervised by

Prof. Dr. Tarek Mohamed Yousef

Professor of Internal Medicine and Gastroenterology

Faculty of Medicine, Ain Shams University

Prof. Dr. Hussein Okasha

Professor of Internal Medicine and Gastroenterology

Faculty of Medicine, Cairo University

Dr. Shereen Abo Bakr Saleh

Assistant Professor of Internal Medicine and Gastroenterology

Faculty of Medicine, Ain Shams University

Dr. Hagar Ahmed Ahmed Elessawy

Lecturer of Internal Medicine and Gastroenterology

Faculty of Medicine, Ain Shams University

**Faculty of Medicine
Ain Shams University**

2019



تقييم البروستاجلاندين ج ٢ كعلامة للتمييز بين الاكياس البنكرياسية
المخاطية وغير المخاطية والتنبؤ بخلل التكيسات البنكرياسية المخاطية

رسالة

توطئة للحصول علي درجة الماجستير في الأمراض الباطنة

مقدمة من

□ هبة حسن عبد الراضي/الطبيبة

بكالوريوس الطب و الجراحة- جامعة عين شمس

تحت إشراف

□ أد/ طارق محمد يوسف

أستاذ أمراض الباطنة العامة والجهاز الهضمي والكبد

كلية الطب- جامعة عين شمس

□ أد/ حسين عكاشة

أستاذ أمراض الباطنة العامة والجهاز الهضمي والكبد

كلية الطب- جامعة القاهرة

□ د/ شيرين أبو بكر صلاح

أستاذ مساعد أمراض الباطنة العامة والجهاز الهضمي والكبد

كلية الطب- جامعة عين شمس

□ د/ هاجر أحمد أحمد العسوي

مدرس أمراض الباطنة العامة والجهاز الهضمي والكبد

كلية الطب- جامعة عين شمس

كلية الطب

جامعة عين شمس

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لَسْبَدَّانِكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgement

*First and foremost thanks to **ALLAH**, the Most Merciful.*

*I wish to express my deep appreciation and sincere gratitude to **Prof. Dr. Tarek Mohamed Yousef**, Professor of Internal Medicine and Gastroenterology, Ain Shams University, for his close supervision, valuable instructions, continuous help, patience, advices and guidance. He has generously devoted much of his time and effort for planning and supervision of this study. It was a great honor to me to work under his direct supervision.*

*I wish to express my great thanks and gratitude to **Prof. Dr. Hussein Okasha**, Professor of Internal Medicine and Gastroenterology, Ain Shams University, for his kind supervision, indispensable advice and great help in this work.*

*I wish to express my great thanks and gratitude to **Dr. Shereen Abo Bakr Saleh**, Assistant Professor of Internal Medicine and Gastroenterology, Ain Shams University, for her kind supervision, indispensable advice and great help in this work.*

*I wish to express my great thanks and gratitude to **Dr. Hagar Ahmed Ahmed Elessawy**, Lecturer of Internal Medicine and Gastroenterology, Ain Shams University, for his kind supervision, indispensable advice and great help in this work.*

*I wish to express my great thanks and gratitude to **Prof. Dr. Mervat I Ansary & Prof. Dr. Safeya El Ansary**, Cairo University, for their kind supervision, indispensable advice and great help in this work.*

Last and not least, I want to thank all my family, my colleagues, for their valuable help and support.

Finally I would present all my appreciations to my patients without them, this work could not have been completed.

CONTENTS

Subjects	Page
• List of Abbreviations	I
• List of table	III
• List of Figures	IV
• Introduction	1
• Aim of the Work.....	4
• Review of literature:	
Chapter 1: Pancreatic Cysts.....	5
Chapter 2: Endoscopic ultrasound.....	39
Chapter 3: Prostaglandin E2	60
• Patients And Methods.....	71
• Results.....	75
• Discussion.....	96
• Summary & conclusion.....	102
• Recommendations.	104
• References	105
• Arabic Summary	-

LIST OF ABBREVIATIONS

5-HETE	: 5-Hydroxy eicosatetraenic
5-HPETE	: 5- hydroperoxy icosatetraenic
5-HTP	: 5- Hydroxytryptophan
ACC	: Adenocarcinoma with cystic lesions
ALOX 15	: Arachidonate 15- lipoxygenase
BD-IPMN	: Branch duct- Intrapapillary mucinous neoplasia
BLT1	: Leukotriene receptor
CA 19-9	: Carbohydrate antigen 19-9
CEA	: Carcinoembryonic antigen
CH-EUS	: Contrast-enhanced harmonic endoscopic ultrasound
COX	: Cyclooxygenase
CPEN	: Cystic pancreatic endocrine neoplasia
CYSLT 1	: Cysteinyl leukotriene
CYSLTR 1	: Cysteinyl leukotriene receptor 1
EFSUMB	: European federation of societies of ultrasound in medicine and biology
ERC	: Endoscopic Retrograde cholangiography
ERCP	: Endoscopic Retrograde cholangiopancreatography
EUS	: Endoscopic Ultrasound
EUS –FNA	: Endoscopic Ultrasound – Fine needle aspiration
EUS-E	: Endoscopic Ultrasound –Elastography
GPCR	: G Protein coupled receptor
IPMN	: Intrapapillary mucinous neoplasia
L-DOPA	: Dihydroxyphenylalanine
LOX	: lipoxygenase
LTA4	: Leukotriene A4
LTB4	: Leukotriene B4
LTC4	: Leukotriene C4
LTD4	: Leukotriene D4
LTE4	: Leukotriene E4
LXA4	: Lipoxin A4
LXB4	: Lipoxin B4
MCN	: Mucinous cystic neoplasia
MDCT	: Multidetector computed tomography

List of Abbreviations

MD-IPMN	: Main duct intrapapillary mucinous neoplasia
MPD	: Main pancreatic duct
MRCP	: Magnetic resonance cholangiopancreatography
nCLE	: Needle- Based confocal laser endomicroscopy
PAF	: Platelet activating factor
PET	: Positron Emission Tomography
PG G2	: Prostaglandin G2
PG H2	: Prostaglandin H2
PGD₂	: Prostaglandin D 2
PGE₁	: Prostaglandin E 1
PGE₂	: Prostaglandin E 2
PGF_{2α}	: Prostaglandin F2α
PGI₂	: Prostaglandin I2
PGS	: Prostaglandin Synthetase
PIP2	: Phosphoinositol biphosphate
PKC	: protein kinase C
PLA2	: Phospholipase A2
PsC	: Pancreatic Pseudocyst
PTGER 2	: PTGER 2 Gene
PTGER 3	: PTGER 3 Gene
PTGER 4	: PTGER 4 Gene
PTGS 1	: Post-transcriptional Gene silencing 1
PTGS 2	: Post-transcriptional Gene silencing 2
SCN	: Serous Cystic Neoplasia
SD	: Standard Deviation
SPEN	: Solid and pseudopapillary epithelial neoplasia
TXA 2	: Thromboxane A 2
TXA1	: Thromboxane A1
TXB 2	: Thromboxane B2
VHL	: Von Hippel Lindau gene

LIST OF TABLE

<i>Tab. No.</i>	<i>Subject</i>	<i>Page</i>
Table (1)	Common Types of Pancreatic cysts	58
Table (2)	Functions of Different Types of Prostaglandins	69
Table (3)	Sex distribution of study groups	75
Table (4)	Age distribution of study groups	76
Table (5)	Cyst classification of study groups	76
Table (6)	Cyst types of study groups	77
Table (7)	Final diagnosis of study groups	78
Table (8)	PGE2 mean & SD upon gender	79
Table (9)	PGE2 mean & SD upon different cyst classification	80
Table (10)	PGE2 mean & SD upon cyst types	81
Table (11)	PGE2 mean & SD upon final diagnosis	82
Table (12)	Grading of dysplasia	83
Table (13)	PGE2 mean & SD of grades of IPMN	84
Table (14)	Descriptive data of PGE2 ,C.F Amylase & CEA	85
Table (15)	Correlation between PGE2 ,C.F Amylase & CEA	86
Table (16)	Correlation between PGE2 ,C.F Amylase & CEA between cyst classification	86
Table (17)	Correlation between PGE2 ,C.F Amylase & CEA between cyst types	87
Table (18)	Correlation between PGE2 ,C.F Amylase & CEA	88

List of Table

	between final diagnosis of pancreatic cyst	
Table (19)	Follow up of recurrence of study groups	89
Table (20)	Follow up of recurrent pancreatitis of study groups	90
Table (21)	PGE2 mean & SD for prediction of recurrence	91
Table (22)	PGE2 mean & SD for prediction of recurrent pancreatitis	92
Table (23)	Sensitivity, specificity, PPV & NPV between true and inflammatory cysts	93
Table (24)	Sensitivity, specificity, PPV & NPV between pseudocysts and MCN	94
Table (25)	Sensitivity, specificity, PPV & NPV between pseudocysts and SCN	95

LIST OF FIGURES

<i>Fig. No.</i>	<i>Subject</i>	<i>Page</i>
Fig. (1)	Anatomy of Pancreas	5
Fig. (2)	Blood Supply of Pancreas	7
Fig. (3)	Typical Presentation of SCN with MDCT	16
Fig. (4)	Typical Presentation of SCN with MDCT	17
Fig. (5)	Typical Presentation of MCN with MDCT	22
Fig. (6)	Features of IPMN in MRI & MDCT	27
Fig. (7)	Features of BD-IPMN in MDCT & MRCP	27
Fig. (8)	MDCT Finding with SPEN	31
Fig. (9)	MRI & MDCT Findings with CPEN	34
Fig. (10)	CT Pelviabdominal with contrast view of metastasis in pancreas	35
Fig. (11)	The View of EUS	39
Fig. (12)	The EUS Equipments	40
Fig. (13)	Different Sizes and Shapes of Metal needle of EUS	42
Fig. (14)	B-mode EUS & EUS-E view of pancreatic masses	50
Fig. (15)	EUS-E & contrast enhancing Doppler view of adenocarcinoma	51
Fig. (16)	B-mode EUS view of Bile stones	59
Fig. (17)	Synthesis of PG &Thromboxane from arachidonic acid	63

List of Figures

<i>Fig. No.</i>	<i>Subject</i>	<i>Page</i>
Fig. (18)	Synthesis of PG & Leuktreine from arachidonic acid	65
Fig. (19)	Synthesis of lipoxin from arachidonic acid	66
Fig. (20)	Sex distribution of study groups	75
Fig. (21)	Cyst classification of study groups	76
Fig. (22)	Cyst types of study groups	77
Fig. (23)	Final diagnosis of study groups	78
Fig. (24)	PGE2 mean & SD upon gender	79
Fig. (25)	PGE2 mean & SD upon different cyst classification	80
Fig. (26)	PGE2 mean & SD upon cyst types	81
Fig. (27)	PGE2 mean & SD upon final diagnosis	82
Fig. (28)	Grading of dysplasia	83
Fig. (29)	PGE2 mean & SD of grades of IPMN	84
Fig. (30)	Follow up of recurrence of study groups	89
Fig. (31)	Follow up of recurrent pancreatitis of study groups	90
Fig. (32)	PGE2 mean & SD for prediction of recurrence	91
Fig. (33)	PGE2 mean & SD for prediction of recurrent pancreatitis	92
Fig. (34)	Sensitivity, specificity, PPV & NPV between true and inflammatory cysts	93
Fig. (35)	Sensitivity, specificity, PPV & NPV between pseudocysts and MCN	94

List of Figures

<i>Fig. No.</i>	<i>Subject</i>	<i>Page</i>
Fig. (36)	Sensitivity, specificity, PPV & NPV between pseudocysts and SCN	95

ABSTRACT

Background: There are different types of pancreatic cysts. They can be classified by different ways. Each of them has different plan of management. That is why their differentiation became mandatory before setting their treatment plans.

Aim of the study: To Evaluate PGE2 as a marker of differentiation of mucin containing pancreatic cysts and prediction of dysplasia in these cysts.

A Secondary aim is differentiation of mucin from non mucin containing pancreatic cystic lesions

Patients and Methods: 40 patients were recruited from The Endoscopy unit of Internal Medicine Department of Cairo University hospital in the period between December 2018 and August 2019. A comparative cohort study design was adopted.

Results: In our study, there were a significant differences in PGE2 level between true and inflammatory pancreatic cysts ($p=0.001$). However, there were insignificant differences between mucinous , non mucinous ($p=0.406$). There were insignificant differences between different grades of IPMN dysplasia ($p=0.615$)

Conclusion: Prostaglandin E2 is pancreatic cystic fluid marker which can be used for differentiation between true pancreatic cysts from inflammatory pancreatic cysts which have different plans of management . Prostaglandin E2 is not good marker to be used for differentiation between different grades of IPMN dysplasia.

Keywords: prostaglandin E2 , intrapapillary mucinous neoplasia , serous cystic neoplasia and mucinous cystic neoplasia.

INTRODUCTION

Many kinds of cysts can grow in the pancreas. These cysts can be classified according to morphology, constituent or malignant tendency. According to constituent, pancreatic cystic lesions is divided into mucin containing cystic lesions and non mucin containing cystic lesions.

The mucin containing lesions is subdivided into mucinous cystic lesions and intra ductal papillary mucinous neoplasm. The non mucin containing cystic lesions is subdivided into pseudocyst and serous cystadenoma (*Michael et al., 2004*).

Intraductal papillary mucinous neoplasm (IPMN) is cystic lesion connected with the pancreatic duct and their fluid usually has a large amount of digestive pancreatic enzymes. The cysts can occur in both men and women and are more common in people older than 50 years. IPMNs are further classified into subtypes based on the presence or absence of dilation of the main pancreatic duct. Cysts that are small, stable in size, and without worrisome features have a low risk of developing into cancers. Worrisome features are defined as a cyst larger than 3 cm, a thick cyst wall or one that “lights up” with contrast when a CT scan is done, size of the main duct of the pancreas measuring 5 to 9 mm, or a sudden change in the diameter of the pancreas’ main duct (*Kristine et al., 2011*).

Another kind of mucinous cyst is called mucinous cystic neoplasm. Less common than IPMNs. Mucinous cystic neoplasms are almost exclusively found in middle-aged women and are usually located in the body and tail of the pancreas. These cysts also potentially can become cancerous.

A third type of cyst is the serous cystadenoma. These cysts have little to no risk of becoming cancerous. They are found more commonly in women older than 50 years (*Masao et al., 2013*).

Another kind of cyst is called a solid pseudopapillary neoplasm. These rare neoplasms have both solid and cystic components. Solid pseudopapillary neoplasms may also become cancerous and are more commonly found in younger women.

Pancreatic ductal adenocarcinoma, the most common form of pancreas cancer, can look cystic in some cases. Pancreatic neuroendocrine tumors, another type of pancreas cancer, can also occasionally appear cystic and be confused with a benign cyst (*Paulo et al., 2016*).

Mucin containing cystic lesions are radiographically detectable and may often be differentiated by optimal imaging (magnetic resonance pancreatography, computed tomography) or endoscopy (Endoscopic Ultrasound or Endoscopic Retrograde Pancreatography). Sometimes, pancreatic fluid analysis for amylase may suggest the